- Home
- BFST vs BCAX Comparison
BFST vs BCAX Comparison
Compare BFST & BCAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BFST
- BCAX
- Stock Information
- Founded
- BFST 2006
- BCAX 2018
- Country
- BFST United States
- BCAX United States
- Employees
- BFST N/A
- BCAX N/A
- Industry
- BFST Major Banks
- BCAX
- Sector
- BFST Finance
- BCAX
- Exchange
- BFST Nasdaq
- BCAX NYSE
- Market Cap
- BFST 838.4M
- BCAX 670.9M
- IPO Year
- BFST 2018
- BCAX 2024
- Fundamental
- Price
- BFST $22.73
- BCAX $12.16
- Analyst Decision
- BFST Buy
- BCAX Buy
- Analyst Count
- BFST 1
- BCAX 7
- Target Price
- BFST $30.00
- BCAX $29.67
- AVG Volume (30 Days)
- BFST 124.1K
- BCAX 516.6K
- Earning Date
- BFST 04-24-2025
- BCAX 05-16-2025
- Dividend Yield
- BFST 2.46%
- BCAX N/A
- EPS Growth
- BFST N/A
- BCAX N/A
- EPS
- BFST 2.26
- BCAX N/A
- Revenue
- BFST $260,702,999.00
- BCAX N/A
- Revenue This Year
- BFST $26.46
- BCAX N/A
- Revenue Next Year
- BFST $5.83
- BCAX N/A
- P/E Ratio
- BFST $10.06
- BCAX N/A
- Revenue Growth
- BFST 6.05
- BCAX N/A
- 52 Week Low
- BFST $18.97
- BCAX $8.91
- 52 Week High
- BFST $30.30
- BCAX $28.09
- Technical
- Relative Strength Index (RSI)
- BFST 43.59
- BCAX N/A
- Support Level
- BFST $20.93
- BCAX N/A
- Resistance Level
- BFST $22.62
- BCAX N/A
- Average True Range (ATR)
- BFST 1.15
- BCAX 0.00
- MACD
- BFST 0.03
- BCAX 0.00
- Stochastic Oscillator
- BFST 56.84
- BCAX 0.00
About BFST Business First Bancshares Inc.
Business First Bancshares Inc is a United States-based bank holding company. The company's services include personal and commercial banking, treasury management, and wealth solutions. It provides a range of financial services to small-to-midsized businesses and professionals. The company generates majority of its revenues from interest income on loans, customer service and loan fees, and interest income from securities.
About BCAX BICARA THERAPEUTICS INC
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.